AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2024
Aug 1, 2024
31920_dirs_2024-08-01_832936b7-97cb-4cdd-a929-c4371188cf80.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2024-07-30
Reporting Person: Palczuk Linda (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-07-30 | Ordinary Shares | A | 11000 | — | Acquired | 63400 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-07-30 | Stock Option (Right to Buy) | $16.32 | A | 11000 | Acquired | 2034-07-30 | Ordinary Shares (11000) | Direct |
Footnotes
F1: Represents restricted share units ("RSUs"). Each RSU represents the contingent right to receive one Ordinary Share upon vesting and settlement. The RSUs shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.
F2: The options shall vest in full on the earlier to occur of (a) July 30, 2025 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service at such time.